The 17β-hydroxysteroid dehydrogenases (17βHSDs) play an important role in the regulation of intracellular levels of biologically active sex steroid hormones in various human tissues. To date, eight distinctive 17βHSD enzymes have been cloned and characterized in humans. Among these isoenzymes, 17βHSD type 2 (17βHSD2) catalyses the conversion of testosterone into androstenedione and/or oestradiol into oestrone in various tissues, and it has thus been suggested to be involved in the biological inactivation of these sex steroids. The human gastrointestinal tract and liver are considered as the principle sites of inactivation and metabolism of various forms of orally administered sex steroids. We therefore examined 17βHSD2 expression and activity in human adult non-pathological gastrointestinal tract in order to clarify further the biological significance of this enzyme. A total of 80 specimens (40 from males and 40 from females) of normal oesophageal, stomach, duodenal, ileal, colonic and rectal tissues were examined for immunohistochemistry. Altogether, 17 tissue specimens were used for enzyme assay, and eight for RNA analysis. 17βHSD2 activity was detected in the stomach, duodenum, ileum, colon and rectum. 17βHSD2 mRNA was most abundant in the small intestine. 17βHSD2 immunoreactivity was localized almost exclusively to the absorptive epithelium, which may be involved in the inactivation of excessive endogenous and exogenous active sex steroids. Results from the present study thus suggest that the human gastrointestinal tract is an important sex steroid metabolizing organ in humans.
INTRODUCTION
It has been demonstrated that biologically active sex steroids can be synthesized in extragonadal tissues from circulating precursors. The transformation of biologically active steroids into inactive or less active compounds and vice versa is considered to be an important mechanism regulating the tissue levels and subsequent actions of bioactive sex steroids. The 17β-hydroxysteroid dehydrogenases (17βHSDs) catalyse the interconversion between neutral and phenolic 17β-hydroxy-and 17-oxo-steroids, such as oestrone and oestradiol, androstenedione and testosterone, 5α-dihydrotestosterone and 5α-androstanedione, etc. [1, 2] . 17β-Hydroxy forms of sex steroids have at least one order of magnitude higher affinity for their respective oestrogen and androgen receptors than the corresponding 17-oxosteroids [1, 2] .
17βHSDs play an essential role in the regulation of intracellular levels of biologically active sex steroid hormones in various human tissues [3] [4] [5] [6] [7] . To date, eight 17βHSD enzyme subtypes have been characterized in humans. All of these isoenzymes possess unique enzymic properties and have distinct tissue distributions [2, [8] [9] [10] [11] [12] [13] . Type 1 17βHSD (17βHSD1) catalyses the conversion of androstenedione into testosterone and\or oestrone into oestradiol using NADPH as a cofactor, while type 2 17βHSD (17βHSD2) catalyses the conversion of testosterone into androstenedione and\or oestradiol into oestrone using NAD + as a cofactor. This isoenzyme has been shown to inactivate sex steroids in the endometrium, placenta and liver [1, 3] .
Steroids that are taken orally are transported from the lumen of the gastrointestinal (GI) tract to hepatocytes via the GI tract mucosa and the portal circulation, prior to reaching the systemic circulation and subsequently the respective target tissues. Therefore the expresssion and activity of steroid-metabolizing enzymes, including 17βHSD2, in the mucosa of the GI tract may play an important role in the systemic metabolism and biological actions of sex steroids. Farthing et al. [14] reported the presence of 17βHSD2 activity in the human jejunal mucosa. Moreover, Miettinen et al. [15] demonstrated the presence of 17βHSD2 mRNA in the human small intestine and colon. Recently, Takeyama et al. [4] reported the expression of both 17βHSD2 mRNA and protein in the human fetal GI tract. Detailed analysis of 17βHSD2 in the adult human GI tract has not, however, been described in the literature to date. Therefore, in the present study, we examined the expression and activity of 17βHSD2 in various regions of the human GI tract in an effort to elucidate further its biological significance in this tissue.
MATERIALS AND METHODS

Tissue collection and preparation
The study was approved by the ethical committee of Tokohu University Hospital.
A total of 80 specimens of non-pathological human adult GI tract tissues were obtained for immunohistochemistry from autopsy and surgical pathology files at Tohoku University Hospital. These comprised 10 oesophageal, 14 stomach, 14 duodenal, 14 ileal, 14 colonic and 14 rectal tissue specimens. The age of the patients from which tissues were obtained ranged from 19 to 85 years (mean age 52 years). Of all specimens, 40 were from male patients and 40 were from female patients. Histological exmination of these specimens revealed no significant pathological abnormalities. Those specimens utilized for enzyme assay (17 specimens) and RNA isolation (eight specimens) were frozen in liquid nitrogen and stored at k80 mC for less than 3 months prior to assay, whereas those used for immunohistochemistry were routinely fixed in 10 % neutral formalin for 24 h at room temperature (23 mC) and then embedded in paraffin wax.
Enzyme assay
Human GI tract tissues were homogenized at 4 mC in phosphate buffer (100 mM KCl, 10 mM KH # PO % , 10 mM NaHPO % and 1 mM EDTA, pH 7.5) using a Potter-Elvehjem glass\Teflon homogenizer, and then centrifuged for 15 min at 1000 g. Aliquots of the supernatant were incubated for 4 h at 37 mC in 0.5 ml of phosphate buffer containing 1 µM "%C-labelled oestradiol and oestrone as substrates, as well as either 10 mM NAD + for oxidative reactions or 10 mM NADPH for reductive reactions (as cofactor). Incubations were terminated and extracted with 2 ml of diethyl ether. The organic phase was evaporated and the residues were subjected to TLC. The developing solvent was cyclohexane\ethyl acetate (1 : 1, v\v). The chromatoplates were autoradiographed for 18 h at room temperature (23 mC). The radioactivity signals were subsequently detected and evaluated using a GS-250 Molecular Image Analyzer (Bio-Rad Laboratories, Hercules, CA, U.S.A.). The protein content of the tissue homogenates was measured by the method of Lowry et al. [16] , using BSA as a standard. Total 17βHSD enzyme activity (reductive or oxidative) was calculated as percentage conversion of the substrate. In the enzyme assay, only one product of the reaction was detected, and no products were formed in the absence of cofactor.
Semi-quantification of the mRNAs for 17βHSD types 1 and 2 by reverse transcription-PCR (RT-PCR) using fluorescent primers
Semi-quantitative analysis was carried out using total RNA fractions from various human GI tract tissues with a specific pair of fluorescent-dye-labelled primers for 17βHSD types 1 and 2 and for β-actin, utilizing methodology described previously [17, 18] . Oligonucleotide primers for RT-PCR were synthesized as shown in Table  1 . The coding sequence between the two PCR primer sites was located 5h-upstream of the RT primer site in each cDNA for 17βHSD1\2 and β-actin. Standard RNAs for 17βHSD types 1 and 2 and for β-actin were synthesized in vitro with T' RNA polymerase using the respective cDNA as a template, purified, and then quantified spectrophotometrically. Total RNA (0.2-2 µg) and standard RNAs (0.02-02 amol) were subjected to RT with Superscript 2 reverse transcriptase (Gibco-BRL, Grand Island, NY, U.S.A.) and a specific antisense primer at 47 mC for 45 min. The resulting cDNA was amplified by PCR using a specific pair of fluorescent-17β-Hydroxysteroid dehydrogenase 2 expression in human gastrointestinal tract 
Immunohistochemical study
Primary antibody
The monoclonal antibody mAb-C2-12 (subclass IgG1κ) was produced by immunizing mice with a synthetic Cterminal peptide corresponding to amino acids 375-387 of 17βHSD2, and was kindly provided by Dr Stefan Andersson (University of Texas Southwestern Medical Center, Dallas, TX, U.S.A.). The detailed characterization of this monoclonal antibody has been reported previously [3] .
Immunostaining
Paraffin-embedded tissues were cut into 3 µm-thick sections and mounted on to clean silane-coated glass slides (Matsunami Co. Ltd, Tokyo, Japan). Following deparaffinization, sections were pretreated by hydrated autoclaving in a sodium citrate buffer (pH 6.0) at 120 mC for 5 min to retrieve antigenicity [19] . The sections were then immersed in methanol containing 0.3 % hydrogen peroxidate for 30 min to block endogenous peroxidase activity. A Histofine kit (Nichirei Co., Tokyo, Japan) was utilized in the immunohistochemical staining procedure for this study. The antigen-antibody complex was visualized with 3,3h-diaminobenzidine. Normal rabbit serum was incubated for 30 min at room temperature (23 mC) to decrease non-specific staining. Sections were then incubated with the primary antibody against 17βHSD2 at a concentration of 1 : 5 for 18 h at 4 mC. After washing, the sections were incubated with biotinylated rabbit anti-(mouse immunoglobulin) and peroxidaseconjugated streptavidin, followed by an incubation in a solution containing 0.05 % hydroxychloride, pH 7.6, 0.06 mM 3,3h-diaminobenzidine and 2 mM hydrogen peroxide. Immunoreactive sections were counterstained with haematoxylin and mounted with a glycerol\gelatin water-soluble medium. As negative controls for immunostaining, sections were incubated with normal mouse IgG instead of primary antibodies ; no specific immunoreactivity was detected in these sections. We used placental tissue as positive control in the immunohistochemical studies.
RESULTS
Enzyme assay
Oxidative 17βHSD activities are summarized in Table  2 . Oxidative 17βHSD activity was detected in the stomach, duodenum, ileum, colon and rectum. All three oesophageal specimens and two out of six stomach specimens showed no oxidative 17βHSD enzyme activity. Reductive 17βHSD enzyme activity was not detected in the oesophagus, stomach, duodenum, ileum, colon or rectum. The recovery of radioactivity was approx. 90 % in this assay. 
Semi-quantification of mRNA levels for 17βHSD types 1 and 2 by RT-PCR
Results of the semi-quantitative analysis of 17βHSD1 and 17βHSD2 mRNAs are summarized in Table 3 . All quantified data are expressed on the basis of β-actin mRNA levels. 17βHSD1 mRNA was not detected in the stomach, duodenum, ileum, colon or rectum, whereas 17βHSD2 mRNA was detected in the oesophagus, stomach, duodenum, ileum, colon and rectum. The greatest amounts of 17βHSD2 mRNA were detected in the small intestine.
Immunohistochemical study
We determined by immunohistochemistry which cell types in the human GI tract express 17βHSD2 (Figure 1) . Results are summarized in Table 4 . 17βHSD2 immunoreactivity was not detected in the squamous epithelium of the oesophagus and oesophageal glands. In the small intestine, colon and rectum, 17βHSD2 immunoreactivity was detected in absorptive epithelial cells. In the stomach, 17βHSD2 immunoreactivity was localized to columnar epithelium undergoing intestinal metaplasia, but was not present in non-metaplastic gastric columnar epithelia or gastric glands. No immunoreactivity was detected in the lamina propria, muscularis mucosae or submucosal layers of the oesophagus, stomach, duodenum, small intestine, colon or rectum. There were no significant differences in the immunolocalization patterns between samples from males and females.
DISCUSSION
In the present study of the human GI tract, 17βHSD2 immunoreactivity was detected almost exclusively in absorptive epithelia. 17βHSD2 in these cells of the GI tract may be involved in the inactivation of excessive biologically active sex steroids which are taken orally, as in the placenta [3, 20] . 17βHSD2 is likely to be involved in the rapid degradation and excretion of steroids in the surface epithelial cells of the GI tract [14, 21] . It is well known that orally administered oestradiol and testosterone are inactivated rapidly and do not enter the circulation in any significant amounts [22, 23] . In recent studies, 17βHSD2 has been reported to metabolize several orally administered steroidal compounds, including those used in oral contraceptives and hormone replacement therapy [24] . 17βHSD2 expression in the GI tract epithelium may therefore play an important role in regulating exposure to orally administered sex steroids via inactivation of these compounds in both the GI tract epithelium and the liver, in which 17βHSD2 has also been reported to be present [14, 25, 26] . The expression of 17βHSD2 in the GI tract absorptive surface epithelia and in hepatocytes may also have a critical function in protecting the human body against exposure to environmental and\or bacterially synthesized sex steroids [27] . This hypothesis is very interesting and attractive when considering recent controversies regarding various biological features of endocrine disruptors. However, it is also true that many of these endocrine disruptors may not be metabolized by 17βHSD2 ; the structural affinity of these compounds for the enzyme needs to be considered [28, 29] . It is possible, therefore, that this important sex steroid metabolizing enzyme in the absorptive epithelium of the human GI tract may have other critical roles with regard to the availability of sex steroids to the local mileu. At present, little is known about the role of 17βHSD2 in the GI tract, and thus further investigations are required in order to clarify the specific functions of this enzyme in human GI epithelia. 17βHSD2 is a member of the short-chain dehydrogenase\reductase family. Of all enzymes in this family, NAD + -dependent 17βHSD2 has the highest identity (45 %) with NAD + -dependent 11βHSD2 [30] . 11βHSD2 possesses a predominant oxidative activity, converting cortisol (11-hydroxy) into cortisone (11-oxo) in specific mineralocorticoid target tissues, such as the 17β-Hydroxysteroid dehydrogenase 2 expression in human gastrointestinal tract kidney, colon and salivary glands. 11βHSD2 plays a very important role in mineralocorticoid actions, especially in the kidney, where this enzyme is believed to function in protecting the mineralocorticoid receptor from occupancy by glucocorticoids via inactivation of cortisol to cortisone [31] . The expression of 11βHSD2 in the colon has been suggested to be associated with the differentiation and maturation of human colon epithelia [32] and gastric acid secretion [33] . Interestingly, the cellular distribution of 11βHSD2 in the human adult GI tract is very similar to that of 17βHSD2 [34] . The expression of 17βHSD2 in the GI tract may also be associated with the differentiation, maturation and functioning of the human GI tract [27, 35, 36] , but further investigations are required 
